Diabetes Mellitus Type 2 Basal Insulin Dosing Requirements Study
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
CGMS with an insulin pump using rapid acting insulin
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring insulin pump, DM Type 2, CGMS, basal rate
Eligibility Criteria
Inclusion Criteria:
- Type 2 diabetes > 3month duration
- Age 18
- Hb A1C <12%
- On any hypoglycemic therapy including insulin for 5 patients and 5 patients naive to insulin and failing oral treatment
- Normal creatine
- Negative for GAD antibodies
- SMBG >4/d and willing/able to comply with study requirements
- Demonstrated adherence to visits and instructions.
Exclusion Criteria
- Severe hypoglycemic during the last month
- Severe cardiac, pulmonary or cerebral disease
- Demonstrated non compliance with clinical recommendations
- Pregnancy, nursing or women who could potentially become pregnant
- Presence of physical, psychological or cognitive impairments that would interfere with adherence to an intensive insulin therapy program or compliance with dietary, diary keeping or maintenance of CGM sensor or pump
Sites / Locations
- Diabetes Care Center
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Insulin Treatment
Arm Description
There is only one arm for this study using lispro insulin administered by insulin pump.
Outcomes
Primary Outcome Measures
What are the mean number of changes in the basal infusion rate(change is defined as any alternation in the basal rate >0.1 U/hr) and what are the mean differences and mean duration (hrs) of these changes.
Secondary Outcome Measures
What mathematical formulas describe the relationship between the dosing factors and do they significantly differ from those previously established by King and Armstrong
Full Information
NCT ID
NCT00874809
First Posted
April 1, 2009
Last Updated
August 23, 2013
Sponsor
Diabetes Care Center
Collaborators
Animas Corporation
1. Study Identification
Unique Protocol Identification Number
NCT00874809
Brief Title
Diabetes Mellitus Type 2 Basal Insulin Dosing Requirements Study
Official Title
A Pilot Study to Explore Basal Insulin Dosing Requirements in Patients With Type 2 Diabetes Treated With Insulin Pump Therapy
Study Type
Interventional
2. Study Status
Record Verification Date
August 2013
Overall Recruitment Status
Completed
Study Start Date
March 2009 (undefined)
Primary Completion Date
December 2011 (Actual)
Study Completion Date
December 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Diabetes Care Center
Collaborators
Animas Corporation
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The main purpose of this study is to determine the number of daily basal insulin rate changes that are needed to achieve short-term near normal glucose control in insulin pump patients with type 2 diabetes
Detailed Description
Subjects will be taught CHO counting after which they will be introduced to an insulin pump. They will wear the insulin pump for three weeks to adjust to the pump and its functions. Then the subject will wear a Continuous Glucose Monitoring System to determine rate changes needed to achieve short-term near normal glucose control. The primary endpoint is what are the mean number of changes in the basal infusion rate and what are the mean differences and mean duration of these changes. The secondary endpoint is what mathematical formulas describe the relationship between the dosing factors and do they significantly differ from those previously established by King and Armstrong.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
insulin pump, DM Type 2, CGMS, basal rate
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Insulin Treatment
Arm Type
Other
Arm Description
There is only one arm for this study using lispro insulin administered by insulin pump.
Intervention Type
Device
Intervention Name(s)
CGMS with an insulin pump using rapid acting insulin
Other Intervention Name(s)
Continuous Glucose Monitoring System (CGMS)
Intervention Description
To determine basal changes subject will wear a CGMS with an insulin pump infusing rapid acting insulin
Primary Outcome Measure Information:
Title
What are the mean number of changes in the basal infusion rate(change is defined as any alternation in the basal rate >0.1 U/hr) and what are the mean differences and mean duration (hrs) of these changes.
Time Frame
week six of study
Secondary Outcome Measure Information:
Title
What mathematical formulas describe the relationship between the dosing factors and do they significantly differ from those previously established by King and Armstrong
Time Frame
week 6 of study
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 2 diabetes > 3month duration
Age 18
Hb A1C <12%
On any hypoglycemic therapy including insulin for 5 patients and 5 patients naive to insulin and failing oral treatment
Normal creatine
Negative for GAD antibodies
SMBG >4/d and willing/able to comply with study requirements
Demonstrated adherence to visits and instructions.
Exclusion Criteria
Severe hypoglycemic during the last month
Severe cardiac, pulmonary or cerebral disease
Demonstrated non compliance with clinical recommendations
Pregnancy, nursing or women who could potentially become pregnant
Presence of physical, psychological or cognitive impairments that would interfere with adherence to an intensive insulin therapy program or compliance with dietary, diary keeping or maintenance of CGM sensor or pump
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Allen B King, MD
Organizational Affiliation
Diabetes Care Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Diabetes Care Center
City
Salinas
State/Province
California
ZIP/Postal Code
93901
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Diabetes Mellitus Type 2 Basal Insulin Dosing Requirements Study
We'll reach out to this number within 24 hrs